Evidence map›Paper›PMID 41525484›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Multiomics identifies a cholesterol-TFEB-PLD3-TLR9 axis driving immunosuppressive tumor-associated macrophage polarization in esophageal squamous cell carcinoma.

Licheng Tan, Hongyu Zhou, Baifeng Zhang, Dora Lai Wan Kwong, Yongxu Jia, Jiayi Huang, Kin To Hugo Siu, Shuang Zhang, Jiao Huang, Jie Luo and 11 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. DHCR24Oncogene · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Licheng Tan *Department of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.ORCID 0000-0003-1181-8505
Hongyu Zhou *Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200000, China.
Baifeng Zhang *Department of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.ORCID 0000-0003-1966-2285
Dora Lai Wan KwongDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.ORCID 0000-0002-1304-2854
Yongxu JiaDepartment of Clinical Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 4500000, China.
Jiayi HuangDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Kin To Hugo SiuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Shuang ZhangDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Jiao HuangDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Jie LuoDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Yuma YangDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.ORCID 0000-0001-5466-7941
Qin LiuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Yingchen LyuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Liuxian BanDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Ziyang QiDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Nanzhou YuDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Chaohui HeDepartment of Cardiovascular Surgery, Songshan Lake Central Hospital of Dongguan City, Dongguan 523000, China.
Weiguang ZhangDepartment of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350000, China.
Yanru QinDepartment of Clinical Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 4500000, China.
Beilei LiuDepartment of Biomedical Sciences, Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong 852, Special Administrative Region, China.
Xinyuan GuanDepartment of Clinical Oncology, Centre for Cancer Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 852, Special Administrative Region, China.ORCID 0000-0002-4485-6017

Funding

Hong Kong Research Grant Concil C7065-18GF C7026-18GF C4039-19GF R4017-18 R1020-18F R7022-20 17119322 T12-703/22-RMOST | National Natural Science Foundation of China (NSFC) 82072738 82273483 82403295
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) reshape the tumor immune microenvironment and promote tumor progression, yet the underlying mechanisms remain largely unclear. Through integration of single-cell RNA (scRNA) sequencing datasets from esophageal squamous cell carcinoma (ESCC), we identified a distinct protumoral macrophage population with elevated expression of phospholipase D3 (PLD3). Multiomics investigations revealed that high infiltration of these PLD3-high macrophages was associated with poor clinical outcomes in ESCC patients. Mechanistically, tumor cells secreted cholesterol to modulate the microenvironment. Upon the uptake by TAMs, cholesterol triggered the nuclear translocation of transcription factor EB (TFEB), which directly bound to the PLD3 promoter region and activated its transcription. The overexpressed PLD3 localized to lysosomes, enzymatically degrading single-stranded nucleic acids, thereby suppressing the activation of the toll-like receptor 9 (TLR9) pathway. This cascade ultimately impaired effector T cell function and sustained an immunosuppressive tumor microenvironment (TME). Notably, therapeutic intervention using ODN2216-siPLD3 in murine models enhanced CD8 T cell infiltration and significantly inhibited tumor growth. Our findings highlight PLD3-high macrophages as a promising diagnostic biomarker and a therapeutic target for ESCC, paving the way for potential clinical translation.

Indexed as

CholesterolEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaPhospholipase DToll-Like Receptor 9Tumor-Associated MacrophagesAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceMultiomicsSignal TransductionTumor MicroenvironmentCholesterolPhospholipase DToll-Like Receptor 9esophageal squamous cell carcinomaimmunotherapymultiomicstolll-like receptor 9tumor-associated macrophages

Identifiers

PMID41525484
PMCPMC12818440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.